Xilio Therapeutics (XLO) Current Deferred Revenue (2024 - 2026)

Xilio Therapeutics (XLO) has 3 years of Current Deferred Revenue data on file, last reported at $31.5 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 60.07% year-over-year to $31.5 million; the trailing twelve-month figure through Mar 2026 stood at $31.5 million (down 60.07% YoY), and the FY2025 full-year result was $40.0 million, up 196.07% from the prior year.
• Current Deferred Revenue slipped to $31.5 million in Q1 2026, from $40.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $79.0 million in Q1 2025 to a low of $13.5 million in Q4 2024.
• A 3-year average of $38.9 million and a median of $31.5 million in 2026 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue soared 263.61% in 2025 and slumped 60.07% in 2026, its largest moves.
• Tracing XLO's Current Deferred Revenue over 3 years: stood at $13.5 million in 2024, then surged by 196.07% to $40.0 million in 2025, then fell by 21.19% to $31.5 million in 2026.
• Business Quant data shows XLO's Current Deferred Revenue at $31.5 million in Q1 2026, $40.0 million in Q4 2025, and $69.3 million in Q3 2025.